Drug Trial Radar · NCT04466748
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jul 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Sep 8, 2015
Primary completion
Dec 29, 2015
Study completion Dec 29, 2015
Sponsor
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A single-center, randomized, double-blinded, placebo parallel controlled phase 1 study to evaluate the safety and pharmacokinetics/pharmacodynamics of multiple (6 days) ascending dose (20mg QD, 40mg QD, 20mg Bid) administrationof Anaprazole in healthy Chinese subjects. 36 subjects, 12 subjects for each dose group. In each dose group, 10 subjects take anaprazole, 2 subjects take placebo.
Conditions
- Healthy Volunteers
Interventions
Anaprazole Sodium enteric-coated tabletDrug
Multiple ascendinng dose, anaprazole 20mg QD(20mg QD group), 40mg QD(40mg QD group), 20mg Bid(20mg Bid group) , 6 days, fasting oral administration.
PlaceboDrug
Multiple dose, 1 tablet QD (20mg QD and 40mg QD group), 1 tablet Bid (20mg Bid group), 6 days, fasting oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse events and serious adverse events as assessed by CTCAE v5.0Time frame: From signing informed consent to study completion, 15 days after fist dose administration
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.